1. Swerdlow SCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). Lyon: IARC; 2017.
2. Dalland JC, Meyer R, Ketterling RP, Reichard KK. Myeloid sarcoma with CBFB-MYH11 Fusion (inv(16) or t(16;16)) prevails in the abdomen. Am J Clin Pathol. 2020;153:333–41.
3. Claerhout H, Van Aelst S, Melis C, Tousseyn T, Gheysens O, Vandenberghe P, et al. Clinicopathological characteristics of de novo and secondary myeloid sarcoma: a monocentric retrospective study. Eur J Haematol. 2018;100:603–12.
4. National Comprehensive Cancer Network. Acute myeloid leukemia (version 3.2020). National Comprehensive Cancer Network. 2019; https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
5. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417–23.